Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients.

Arthritis and rheumatism - 1 Apr 2004

Martinez Alfonso, Salido Marina, Bonilla Gema, Pascual-Salcedo Dora, Fernandez-Arquero Miguel, de Miguel Sonia, Balsa Alejandro, de la Concha Emilio G, Fernandez-Gutierrez Benjamin

Abstract excerpt

OBJECTIVE: To determine whether major histocompatibility complex (MHC) polymorphisms are associated with a good or poor response to infliximab therapy in patients with rheumatoid arthritis (RA). METHODS: Seventy-eight infliximab-treated patients with RA were genotyped for HLA-DRB1, HLA-DQA1, HLA-...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antirheumatic Agents
Share to Histocompatibility Antigens Class I

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-DQ alpha-Chains

Share to HLA-DQ Antigens

Share to HLA-DQ beta-Chains

Share to HLA-DRB1 Chains

Share to Infliximab

Share to Lymphotoxin-alpha

Source

Identifiers

PMID: 15077289
DOI: 10.1002/art.20154

Genes

MICA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-15077289-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients.PMID 15077289Read ↗

Genetic polymorphisms of tumour necrosis factor receptor superfamily 1A and 1B affect responses to infliximab in Japanese patients with Crohn's disease.Semantic proximity Read ↗

Role of TNFRSF1B polymorphisms in the response of Crohn's disease patients to infliximab.Semantic proximity Read ↗

FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis.Semantic proximity Read ↗

Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy.Semantic proximity Read ↗

The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept.Semantic proximity Read ↗

Genetic polymorphisms of tumour necrosis factor receptor superfamily 1b and fas ligand are associated with clinical efficacy and/or acute severe infusion reactions to infliximab in Crohn's disease.Semantic proximity Read ↗

HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis.Semantic proximity Read ↗

A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.Semantic proximity Read ↗

Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis.Semantic proximity Read ↗

Association of HLA-DR genotypes and IL-1ra gene polymorphism with treatment failure of budesonide and disease patterns in Crohn's disease.Semantic proximity Read ↗

HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases.Semantic proximity Read ↗

Impact of HLA-DQA1*05 Genotype in Immunogenicity and Failure to Treatment with Tumour Necrosis Factor-alpha Antagonists in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.